ZHU Lizhe , DU Jinsui , DUAN Chenglong , YU Shuyao , NAN Zhaoli , WANG Bin , REN Yu
  • Department of Breast Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, P. R. China;
REN Yu, Email: renyyyyy@126.com
human epidermal growth factor receptor 2; young early breast cancer; clinicopathological characteristics; prognosis
10.7507/1007-9424.202407095
Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables References Cited by

Objective To compare the clinicopathological characteristics and prognosis of young early breast cancer patients with different human epidermal growth factor receptor 2 (HER2) expression levels, and to analyze the clinicopathological characteristics and prognosis of young early breast cancer patients with low HER2 expression. Methods A total of 1 723 breast cancer patients who were treated in the Department of Breast Surgery of the First Affiliated Hospital of Xi’an Jiaotong University between June 2016 and June 2018 were collected and divided into three groups: HER2-negative, low-expression, and high-expression. The clinicopathological characteristics of the three groups were compared, and the relationship between HER2 expression and patients’ prognosis was analyzed. Results There were 512 HER2-negative patients, 748 HER2-low expression patients, and 463 HER2-high expression patients. The results of the clinical pathological characteristics analysis of the three groups of patients showed that there were no statistical differences in marital status, menopausal status, family history, single T stage (tumor size), single M stage (distant metastasis), affected side, vascular tumor thrombus, and radiotherapy in the three groups of breast cancer patients with different HER2 expression levels (P>0.05). However, there were statistical differences in age, Ki-67 expression level, N stage, TNM stage, surgical method, estrogen receptor and progesterone receptor status, histological type, histological grade, whether to receive neoadjuvant therapy and adjuvant chemotherapy in breast cancer patients with different HER2 expression levels (P<0.05). The results of survival analysis showed that the prognosis of early breast cancer patients may not be significantly correlated with the HER2 expression level, and the prognosis of young early breast cancer patients may also not be statistically correlated with the HER2 expression status. Conclusions Breast cancer patients with different HER2 expression levels differ in multiple clinicopathological characteristics, but these differences do not significantly affect the prognosis of the patients. Especially for early-stage breast cancer, HER2 expression levels do not seem to have a significant impact on prognosis. This suggests that HER2 status may not be a decisive factor in treatment and prognosis assessment, and other pathological characteristics and treatment methods need to be considered comprehensively. The prognosis of young breast cancer patients in early stage may also not be statistically correlated with HER2 expression status.

Citation： ZHU Lizhe, DU Jinsui, DUAN Chenglong, YU Shuyao, NAN Zhaoli, WANG Bin, REN Yu. Clinicalpathological characteristics and prognostic analysis of young early breast cancer patients with low HER2 expression. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2024, 31(9): 1038-1045. doi: 10.7507/1007-9424.202407095 Copy

  • Previous Article

    Advances in the diagnosis and treatment of early breast cancer

  • Next Article

    Laparoscopically harvested pedicled omental flap for one-stage breast reconstruction：An analysis of 16 cases was presented